Clinical Trials
15 trialsNCT07221149 2026-05-14
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT07221357 2026-05-06
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT00208260 2026-02-05
Intensified Chemotherapy in CRC After Resection of Liver Metastases
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2/3 Completed
NCT05171166 2025-12-18
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
Peking University
Phase 2/3 Terminated
NCT05033522 2025-10-23
ALIVE
Mirror Biologics, Inc.
Phase 2/3 Suspended
NCT05462613 2024-12-20
REPROGRAM-02
Centre Hospitalier Universitaire de Besancon
Phase 2/3 Recruiting
NCT06662877 2024-10-29
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
Sun Yat-sen University
Phase 2/3 Not yet recruiting
NCT01515787 2024-02-02
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
Alliance for Clinical Trials in Oncology
Phase 2/3 Unknown
NCT03957733 2022-04-06
Phase II/III Study to Assess the Efficacy of Neoadjuvant Consolidation Chemotherapy in Rectal Cancer Patients.
King Abdullah Medical City
Phase 2/3 Unknown
NCT03031444 2021-02-01
PARECEC
Peking University Cancer Hospital & Institute
Phase 2/3 Completed
NCT02527772 2019-06-04
LD-FOX4/HCC
Guangxi Medical University
Phase 2/3 Withdrawn
NCT02534337 2019-06-04
Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma
Guangxi Medical University
Phase 2/3 Withdrawn
NCT00384176 2017-04-14
HORIZON III
AstraZeneca
Phase 2/3 Completed
NCT02882269 2016-08-30
Neoadjuvant Chemotherapy for the Treatment of Resectable Locally Advanced Colon Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2/3 Unknown
NCT02590367 2015-12-02
Estimate the Efficacy of HD6610 Granule for Oxaliplatin-induced Peripheral Neuropathy
Jiangsu Province Hospital of Traditional Chinese Medicine
Phase 2/3 Unknown